Mutational activation of PIK3CA detected in tumor tissue has been found in association with both an adverse clinical outcome of patients in multiple solid tumors and can predict a favorable response to PIK3CA inhibitors [10]. The gene discussed is PIK3CA; the disease is neoplasm.